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Background: Women with gestational diabetes mellitus (GDM) are at an increased risk of developing metabolic
syndrome (MetS) after delivery. Recently, the prevalence of both GDM and MetS has increased worldwide, in
parallel with obesity. We investigated whether the presentation of MetS and its clinical features among women
with previous GDM differs from that among those with normal glucose tolerance during pregnancy, and whether
excess body weight affects the results.
Methods: This hospital-based study of two cohorts was performed in Kanta-Häme Central Hospital, Finland. 120 women
with a history of GDM and 120 women with a history of normal glucose metabolism during pregnancy, all aged
between 25 and 46 were enrolled. They all underwent physical examination and had baseline blood samples
taken. All 240 women were also included in subgroup analyses to study the effect of excess body weight on the results.
Results: Although the groups did not differ in body mass index (BMI; p = 0.069), the risk of developing MetS after
pregnancy complicated by GDM was significantly higher than after normal pregnancy, 19 vs. 8 cases (p = 0.039).
Fasting glucose (p < 0.001) and triglyceride levels (p < 0.001) were significantly higher in women affected. In subgroup
analysis, cardiovascular risk factors were more common in participants with high BMI than in those with previous
gestational diabetes.
Conclusions: The risk of MetS was 2.4-fold higher after GDM than after normal pregnancy. Cardiovascular risk factors
were more common in participants with high BMI than in those with previous GDM. Multivariate analysis supported
the main findings. Weight control is important in preventing MetS after delivery.
Keywords: Gestational diabetes mellitus, Metabolic syndrome, Body mass index, Body weight excess,
Cardiovascular risk factorsIntroduction
The prevalence of gestational diabetes mellitus (GDM)
has increased globally in recent decades along with
increasing rates of obesity and inactive lifestyles [1,2]. In
Finland, GDM affected 15.0% of pregnancies in 2013 [1].
Glucose intolerance normalizes after delivery in most
cases [3,4], but women with a history of GDM have at
least a sevenfold risk of developing type 2 diabetes in
the future [5]. Affected women are also at an increased
risk of developing cardiovascular disease or metabolic
syndrome (MetS) years after the pregnancy [6-9].* Correspondence: tiina.vilmi-kerala@khshp.fi
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unless otherwise stated.Metabolic syndrome is an international health prob-
lem considered to be the result of concomitant accumu-
lation of abdominal obesity, hypertension, dyslipidaemia
and abnormal glucose tolerance or diabetes [10]. In re-
cent decades, the prevalence of MetS has rapidly in-
creased in parallel with sedentary lifestyles [6], leading to
major healthcare costs. The chance of developing car-
diovascular disease is six to eight times higher and that
of mortality related to cardiovascular disease two to
three times higher among the MetS population than
among healthy controls [11-14].
Gestational diabetes mellitus shares common features
with MetS, including dyslipidaemia, insulin resistance
and endothelial dysfunction [15-19]. Several studies have
revealed an increased risk of MetS in association with a
history of GDM [7,20,21]. For example, a Danish studyntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 2 Clinical characteristics in the GDM and control
groups
GDM Control p value
(n = 120) (n = 120)
Age at follow-up, years 35.8 ± 4.4 35.9 ± 4.6 NS
Family history of
- Coronary heart disease, n (%) 20 (16.7%) 23 (19.2%) NS
- Cerebrovascular disease, n (%) 15 (12.5%) 5 (4.2%) 0.033
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with a history of GDM was threefold higher than in the
general age-matched population [7]. However, other
studies have shown contrasting results, with no associ-
ation between GDM and MetS [22,23].
Women’s health after GDM has been widely stud-
ied. However, the effect of an overweight condition
on health after GDM or after normal pregnancy is
less well known. The aim of our hospital-based study
of two age-matched cohorts was to reveal whether or
not the presentation of MetS and its individual vari-
ables among women with previous GDM differs from
those with normal glucose metabolism a few years
after delivery. In this first study of the Hämeenlinna
GDM Research Programme, we also wanted to inves-
tigate if there is a difference in clinical features be-
tween the groups and whether excess body weight
affects the results.
Methods
We investigated a total of 120 parturients from our area
aged 25 to 46 years and with a history of GDM during
the index pregnancy and we compared them with 120
age-matched women with normal glucose metabolism
during pregnancy. Power analyses were conducted toTable 1 Characteristics of the index pregnancy in the
GDM and control groups
GDM Control p value
(n = 120) (n = 120)
75-g OGTT
- 0 h, mmol/L 5.4 ± 0.5 4.7 ± 0.3 < 0.001
- 1 h, mmol/L 9.5 ± 2.3 7.1 ± 1.4 < 0.001
- 2 h, mmol/L 7.7 ± 2.0 5.8 ± 1.0 < 0.001
Pregnancy disorders
- Gestational hypertension, n (%) 12 (10%) 6 (5%) NS
- Pre-eclampsia, n (%) 7 (5.8%) 2 (1.7%) NS
- Glucosuria, n (%) 25 (20.8%) 4 (3.3%) < 0.001
- Proteinuria, n (%) 19 (15.8%) 7 (5.8%) 0.021
Induction of delivery, n (%) 42 (35.0%) 26 (21.7%) 0.031
Caesarean section, n (%) 29 (24.2%) 21 (17.5%) NS
Perinatal outcome
- Gestational age, days 277.1 ± 9.5 278.8 ± 10.4 NS
- Birth weight of the child, g 3633 ± 519 3540 ± 471 NS
- Apgar score at one minute 8.6 ± 1.2 8.7 ± 1.4 NS
- Apgar score at five minute 9.3 ± 0.8 9.3 ± 0.8 NS
- Umbilical blood arterial pH 7.29 ± 0.1 7.28 ± 0.1 NS (0.054)
- Umbilical blood venous pH 7.35 ± 0.1 7.35 ± 0.1 NS
Data are presented as mean ± SD if not mentioned otherwise.
OGTT: Oral glucose tolerance test.estimate the required number of participants. Concern-
ing continuous variables, we worked on a difference of
10% with a standard deviation of 25% (Cohen’s d = 0.40).
Regarding the presentation of MetS the expected pro-
portions were 10% and 25%. When the significance level
was set at 5% and power at 80%, the estimated numbers
of participants as regards continuous and categorial vari-
ables were 99 and 100 in both groups, respectively. In
Kanta-Häme Central Hospital, Finland, there are ap-
proximately 1700 deliveries annually. The electronic
database of the hospital was used to pick up the cases
and controls. Both recruitment and examinations were
carried out between August 2011 and July 2014.- Diabetes mellitus, n (%) 32 (26.7%) 27 (22.5%) NS
Diagnosed disorder, n (%) 52 (43.3%) 45 (37.5%) NS
- Hypertension, n (%) 3 (2.5%) 5 (4.2%) NS
- Type 1 diabetes mellitus, n (%) 2 (1.7%) 0 (0%) NS
- Type 2 diabetes mellitus, n (%) 1 (0.8%) 0 (0%) NS
- Polycystic ovary syndrome, n (%) 8 (6.7%) 1 (0.8%) 0.036
Permanent medication for any
chronic disease, n (%)
43 (35.8%) 35 (29.2%) NS
Contraception, n (%) 99 (82.5%) 92 (76.7%) NS
Smoking status 0.018
- Current, n (%) 24 (20.0%) 12 (10%)
- Former, n (%) 45 (37.5%) 37 (30.8%)
- Never, n (%) 51 (42.5%) 71 (59.2%)
BMI, kg/m2 28.3 ± 5.0 27.5 ± 5.4 NS (0.069)
Waist circumference, cm 96.8 ± 13.0 92.5 ± 12.6 0.009
Systolic blood pressure, mmHg 122.4 ± 12.5 119.0 ± 11.5 0.034
Diastolic blood pressure, mmHg 73.5 ± 9.0 71.8 ± 8.7 NS
Heart rate, beats per minute 65.9 ± 9.1 63.8 ± 9.6 0.017
MetS, n (%) 19 (15.8%) 8 (6.7%) 0.039
- Waist circumference > 88 cm, n (%) 89 (74.2%) 73 (60.8%) 0.038
- Blood pressure ≥ 130/85 mmHg, n (%) 35 (29.2%) 25 (20.8%) NS
- HDL cholesterol < 1.30 mmol/L, n (%) 23 (19.2%) 22 (18.3%) NS
- Triglycerides ≥ 1.7 mmol/L, n (%) 12 (10.0%) 5 (4.2%) NS (0.084)
- Glucose ≥ 6.1 mmol/L or diabetes,
n (%)
18 (15.0%) 4 (3.3%) 0.002
Data are presented as mean ± SD if not mentioned otherwise. Metabolic
syndrome and separate variables defined by NCEP.
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– Index pregnancy and delivery 2–6 years before
participating in the study
– GDM group: GDM defined as a pathological
value in the 75-g oral glucose tolerance test
(OGTT) during the pregnancy; venous plasma
glucose ≥ 5.3 mmol/L when fasting, ≥ 10.0 mmol/L
at 1 hour or ≥ 8.6 mmol/L at 2 hours. The diagnostic
criteria of GDM were the same as in current Finnish
guidelines [24].
– Control group: normal OGTT results during the
pregnancy and birth weight of the newborn < 4.5 kg
Exclusion criteria were as follows:
– Multiple pregnancy
– Suspected or verified endocrine or malignant disease
– Treatment of or known clinical history of psychiatric
illness
– Substance abuse
– GDM group: diagnosed type 1 or 2 diabetes before
the index pregnancy
– Control group: GDM in earlier pregnancy
Resting blood pressure and heart rate, weight (kg),
height (cm) and waist circumference (cm) of theFigure 1 Pack-years of smoking in the GDM and control groups. Pack-year
previous history of GDM vs. women unaffected. The median in both group
number of pack-years in the GDM group was 3.1 (±6.1) and in the controlparticipants were measured. Body mass index (BMI) was
calculated as weight in kilograms divided by height in
meters squared (kg/m2). Metabolic syndrome was de-
fined according to the National Cholesterol Education
Program (NCEP Adult Treatment Panel III) as the pres-
ence of at least three of the following five criteria [10]:
– waist circumference > 88 cm
– serum triglycerides ≥ 1.7 mmol/L
– serum high-density lipoprotein (HDL) cholesterol
level < 1.3 mmol/L
– blood pressure ≥ 130/85 mmHg
– plasma glucose level ≥ 6.1 mmol/L or diabetes
mellitus
Further, we interviewed the participants as regards
their medical histories and lifestyle habits. Initially suc-
cessful weight loss followed by weight regain (so called
“yo-yo” dieting or weight cycling) is associated with body
weight excess and abdominal fat accumulation [25]. To
analyse “yo-yo” dieting, we estimated total lifetime
weight loss by adding together kilograms lost during
every previous intentional weight-loss period. Lifetime
tobacco exposure was calculated as pack-years by multi-
plying smoking years with average packs smoked daily
[26]. One pack-year is defined as twenty cigarettes
smoked every day for one year.s of smoking differed significantly (p = 0.012) between women with a
s was zero, because the majority were non-smokers. The mean (±SD)
group, 1.6 (±4.4).
Table 3 Laboratory characteristics of participants with
GDM vs. controls
GDM Control p value
(n = 119) (n = 120)
Leucocytes, 109/L 5.8 ± 1.6 5.2 ± 1.4 0.008
Haemoglobin, g/L 133.2 ± 9.3 128.6 ± 12.9 0.001
Platelets, 109/L 241.9 ± 58.2 244.0 ± 52.5 NS
ALAT, U/L 22.8 ± 17.4 19.7 ± 10.5 NS
Creatinine, umol/L 66.6 ± 7.7 64.5 ± 7.8 0.048
U-AlbCre, mg/mmol 0.67 ± 0.5 0.57 ± 0.3 NS (0.070)
Fibrinogen, g/L 3.4 ± 0.9 3.2 ± 1.0 NS (0.096)
Fasting glucose, mmol/L 5.6 ± 0.6 5.3 ± 0.3 < 0.001
Total cholesterol, mmol/L 4.7 ± 0.9 4.6 ± 0.8 NS
HDL cholesterol, mmol/L 1.5 ± 0.3 1.6 ± 0.3 NS
LDL cholesterol, mmol/L 3.0 ± 0.7 2.8 ± 0.6 NS
Triglycerides, mmol/L 1.1 ± 0.6 0.9 ± 0.4 < 0.001
Data are presented as mean ± SD.
U-AlbCre: urinary albumin to creatinine ratio, ALAT: alanine transaminase.
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MetS and its different variables in the GDM and control
groups. We also wanted to see if there were differences in
medical history, lifestyle habits, pregnancy outcomes or
clinical characteristics between the groups. The secondary
aim was to investigate the influence of excess body weight
on these results.
Every participant was given both oral and written infor-
mation on the study before she signed an informed consent
document. The study protocol was approved by the Ethics
Committee of Kanta-Häme Hospital District and the study
followed the ethical principles outlined in the Declaration
of Helsinki [27].Table 4 Clinical characteristics of non-obese GDM cases and t
GDM cases
BMI ≥ 27 BM
(n = 65) (n
Systolic blood pressure, mmHg* 126.6 ± 12.3 11
Diastolic blood pressure, mmHg* 76.1 ± 9.6 70
Mean peripheral pressure, mmHg* 94.0 ± 10.7 87
Heart rate, beats per minute 66.6 ± 8.9 65
MetS, n (%) 15 (23.1 %) 4
- Waist circumference > 88 cm, n (%) 62 (95.4 %) 27
- Blood pressure ≥ 130/85 mmHg, n (%) 27 (41.5 %) 8
- HDL cholesterol < 1.30 mmol/L, n (%) 14 (21.5 %) 9
- Triglycerides ≥ 1.7 mmol/L, n (%) 9 (13.8 %) 3
- Glucose ≥ 6.1 mmol/L or diabetes, n (%) 11 (16.9 %) 7
Metabolic syndrome and separate variables defined by NCEP.
Data are presented as mean ± SD if not mentioned otherwise.
*Differences between non-obese GDM cases and their controls, and obese GDM ca
comparisons were significant.Basic blood count and serum levels of creatinine, alanine
transaminase (ALAT), fasting glucose, total cholesterol,
HDL cholesterol, low-density-lipoprotein (LDL) cholesterol
and triglycerides, and the urinary albumin to creatinine ra-
tio, as well as fibrinogen, were analysed according to vali-
dated methods after at least 12 hours of fasting. Direct
analyses of total cholesterol, HDL cholesterol, LDL choles-
terol and triglycerides were carried out by using commer-
cial reagents from Beckman Coulter (Brea, CA, USA).
Analyses of ALAT (IFCC method), creatinine (Jaffé
method) and plasma glucose (hexokinase method) were
carried out by using commercial reagents from Beckman
Coulter, with an Olympus AU640 analyser and analyses of
fibrinogen (Clauss method) by using Siemens BCS XP
equipment.Statistical analyses
Statistics were analysed by using IBM® SPSS® Statistics Ver-
sion 22 software (copyright 2013). Variables were tested for
normality by way of Shapiro–Wilk or Kolmogorov–Smir-
nov tests, as appropriate. Data are presented as mean ±
standard deviation (SD) if not mentioned otherwise.
Differences in continuous variables between GDM par-
ticipants and controls were studied by using Student's t-
test in cases of normality and by the Mann–Whitney
U-test in cases of non-normality. Categorial data are
presented as percentages and were compared by using
the chi-square test. All 240 women were also included
in subgroup analyses to study the effect of excess body
weight on the results. For these analyses, we divided
the whole study group into two halves according to
BMI, using a cut-off point of 27 kg/m2. According to
the FINRISK 2012 Study our BMI cut-off of 27 kg/m2heir controls, and obese GDM cases and their controls
Controls Overall
I < 27 BMI ≥ 27 BMI < 27 p value
= 55) (n = 57) (n = 63)
7.7 ± 11.2 122.8 ± 12.4 116.1 ± 9.1 < 0.001
.5 ± 9.6 74.6 ± 8.1 69.1 ± 8.5 < 0.001
.0 ± 8.4 91.5 ± 9.3 85.3 ± 8.8 < 0.001
.2 ± 9.3 65.2 ± 9.0 62.6 ± 10.1 NS
(3.3 %) 8 (14.0 %) 0 (0 %) < 0.001
(49.1 %) 53 (93.0 %) 20 (31.7 %) < 0.001
(14.5 %) 19 (33.3 %) 6 (9.5 %) < 0.001
(16.4 %) 14 (24.6 %) 8 (12.7 %) NS
(5.5 %) 4 (7.0 %) 1 (1.6 %) NS (0.050)
(12.7%) 1 (1.8 %) 3 (4.8 %) 0.012
ses and their controls were non-significant; differences in other subgroup
Figure 2 (See legend on next page.)
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Figure 2 Lifetime weight loss, fasting glucose and alanine transaminase in the subgroups. A: Median (minimum, maximum) lifetime weight loss
among obese (BMI≥ 27) GDM women was 20 (0, 116) kg, among obese control women 20 (0, 100) kg, among non-obese GDM women 8 (0, 100) kg
and among non-obese control women 0 (0, 70) kg. B: Median (minimum, maximum) fasting glucose levels among obese GDM women 5.6 (4.6, 7.9)
mmol/L, among obese control women 5.2 (4.4, 6.2) mmol/L, among non-obese GDM women 5.4 (4.6, 9.8) mmol/L and among non-obese control
women 5.2 (4.5, 6.1) mmol/L. C: Median (minimum, maximum) alanine transaminase levels among obese GDM women 21 (10, 122) U/L, among obese
control women 17 (9, 53) U/L, among non-obese GDM women 16 (9, 48) U/L and among non-obese control women 16 (9, 82).
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women [28]. Medicines agencies also define the cut-off
point of overweight as a BMI of 27 kg/m2 [29]. There
were 122 women in the “obese” group (BMI ≥ 27); 65
GDM and 57 control participants. The “non-obese”
group (BMI < 27; n = 118) consisted of 55 GDM and 63
control participants. The clinical characteristics of these
four subgroups were studied by way of one-way
ANOVA in cases of normality and by using the
Kruskal–Wallis test in cases of non-normality. Post hoc
analyses were performed, when appropriate. Logistic re-
gression analysis was carried out to identify predictors
as regards the presentation of MetS. First, univariate
analysis was carried out. The set of independent vari-
ables tested included previous GDM, maternal age,
BMI, family history of diabetes mellitus, pack-years of
smoking, total lifetime weight loss, method of treatment
among GDM cases, birth weight of the newborn, time
from delivery to the present study and serum concen-
tration of total cholesterol. The significant independent
variables were then entered into multivariate analysis.
The results are expressed as odds ratios (ORs) and 95%
confidence intervals (CIs). A two-tailed probability
value of < 0.05 was considered significant.
Results
Basic information on the index pregnancy in the GDM
and control groups is shown in Table 1. All GDM partic-
ipants and controls underwent a 75-g OGTT during the
index pregnancy. A total of 25 GDM participants had
medication during their pregnancies (insulin, n = 24;
metformin, n = 1), while the other mothers in the GDM
group had only dietary therapy. Twenty-three of the 120
women were primiparous in both groups. Nearly a third
(29.9%, n = 29/97) of the multiparous GDM partici-
pants had already experienced GDM in an earlier preg-
nancy. Accumulation of gestational hypertension and
pre-eclampsia was more common in diabetic pregnan-
cies (p = 0.038). There was more glucosuria and protein-
uria in pregnancies affected by GDM, as shown in
Table 1.
The average time to follow-up was 3.7 years in both
study groups. Clinical characteristics in women with
and without previous GDM are shown in Table 2.
According to our study interview data there were
more current or former smokers in the GDM groupthan in the control group, and also the pack-years of
smoking differed significantly (Figure 1). The groups
did not differ in physical activity, alcohol intake or
lifetime weight loss. The GDM group used less mar-
garine weekly than the control group (n = 64 vs. 81;
p = 0.034), but on the other hand the groups did not
differ in weekly use of butter (n = 69 vs. 66). The
GDM participants also consumed fewer sweets and
sweet baked goods weekly (n = 95 vs. 111; p = 0.005)
than the controls. Otherwise, we found no other dif-
ferences in basic nutrition habits between the groups.
Despite a current Finnish guideline recommending
OGTT screening six to twelve weeks after delivery in
cases of medicated GDM during pregnancy, and one
year after delivery in diet-treated GDM during preg-
nancy [24], only 41 of the 120 women (34.2%) with a
history of GDM had an OGTT after delivery. Of these,
39.0% (16/41) showed glucose intolerance as follows:
17.1% (7/41) had impaired fasting glucose (IFG), 14.6%
(6/41) had impaired glucose tolerance (IGT) and 7.3%
(3/41) had diabetes. The results of OGTTs were normal
in 25 of the 41 cases.
Clinical chemical data concerning the women with
and without previous GDM are presented in Table 3.
Between the groups, there were significant differences
in serum concentrations of fasting glucose and triglyc-
erides, both of them variables of MetS. When GDM
participants with medication (n = 25) were compared
with those with dietary therapy (n = 95) during the
index pregnancy, we noticed a significant difference
only in fasting glucose (6.0 ± 1.0 vs. 5.5 ± 0.4 mmol/L; p
= 0.003). As shown in Table 2, the women in the GDM
group met the criteria of MetS 2.4-fold more often than
did the controls. The numbers of participants with sep-
arate variables of metabolic syndrome defined by NCEP
are also shown in Table 2.
In subgroup analyses, MetS affected participants in
obese subgroups more often than in non-obese sub-
groups, as shown in Table 4. These four subgroups,
obese GDM cases and their controls, and non-obese
GDM cases and their controls, did not differ signifi-
cantly in family history of cardio- or cerebrovascular
diseases, medical history, medication, contraception,
physical activity or alcohol consumption. Pack-years of
smoking among non-obese GDM women were 2.7 (±3.5),
among obese GDM women 4.7 (±7.5), among non-obese
Figure 3 (See legend on next page.)
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Figure 3 HDL cholesterol, LDL cholesterol and triglyceride levels in the subgroups. A: The median (minimum, maximum) HDL cholesterol level
among obese (BMI≥ 27) GDM women was 1.4 (0.8, 2.7) mmol/L, among obese control women 1.4 (1.0, 2.4) mmol/L, among non-obese GDM
women 1.5 (0.8, 2.3) mmol/L and among non-obese control women 1.5 (1.1, 2.7) mmol/L. B: The median (minimum, maximum) LDL cholesterol
level among obese GDM women was 3.1 (2.0, 5.3) mmol/L, among obese control women 3.0 (1.7, 4.8) mmol/L, among non-obese GDM women
2.6 (1.6, 4.2) mmol/L and among non-obese control women 2.7 (1.6, 3.8) mmol/L. C: The median (minimum, maximum) triglyceride level among
obese GDM women was 1.2 (0.4, 4.4) mmol/L, among obese control women 0.9 (0.5, 2.0) mmol/L, among non-obese GDM women 0.8 (0.4, 3.5)
mmol/L and among non-obese control women 0.6 (0.4, 1.8) mmol/L.
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women 3.3 (±5.5) (p = 0.058). The subgroups did not differ
significantly in perinatal outcomes either. There was a
major difference in lifetime weight loss (Figure 2A), both
obese GDM and obese control women having lost more
weight than non-obese GDM and control women. There
were differences in most of the basic clinical characteristics
between these four subgroups, particularly between non-
obese and obese subgroups, as demonstrated in Figures 2B,
C and 3A–C, and Table 4.
In univariate logistic regression analysis, previous
GDM (OR 2.63, 95% CI 1.11–6.28; p = 0.029), higher
BMI values (OR 1.24, 95% CI 1.14–1.35; p < 0.001),
greater lifetime weight loss (OR 1.02, 95% CI 1.00–1.03;
p = 0.013) and higher levels of total cholesterol (OR 1.98,
95% CI 1.26–3.10; p = 0.003) were associated with an
increased risk of MetS. Multivariate analysis also
showed that previous GDM (OR 2.83, 95% CI 1.05–
7.63; p = 0.040), higher BMI values (OR 1.24, 95% CI
1.13–1.36; p < 0.001) and higher serum concentra-
tions of total cholesterol (OR 1.68, 95% CI 1.01–2.79;
p = 0.046) seemed to predict the presentation of MetS.
No other associations were found in logistic regression
analyses.
Discussion
The main finding in our study was that the risk of devel-
oping MetS after GDM was 2.4-fold greater than after
normal pregnancy. However, cardiovascular risk factors
such as increased LDL cholesterol and triglyceride levels
as well as decreased HDL cholesterol concentrations
were more common in participants with high BMI than
in those with previous GDM.
A systematic review conducted in 2014 demonstrated
that women who have had GDM have a nearly fourfold
increased risk of developing MetS in the future than
those who have had a normal pregnancy. However, there
are some factors that may modify the risk of developing
MetS after GDM. For example, ethnicity may signifi-
cantly affect MetS susceptibility. BMI is also an import-
ant confounder in the overall MetS risk estimate. When
MetS after GDM was grouped by BMI, the odds ratio
was 2.53 according to recent meta-analyses [6]. In our
study, both the participants and the controls were ofCaucasian origin, and there was no significant difference
between the groups in BMI or body weight. Our results
are in accordance with results reported earlier [6].
The results of previous studies indicate that there is a
relationship among the risk gene variants as regards
both GDM and MetS [30-32]. Possibly, genetic factors
also protect obese control women against insulin resist-
ance and, on the other hand, expose non-obese or even
lean GDM women to glucose intolerance during preg-
nancy. At the same time, non-obese GDM women seem
to have a better cardiovascular profile a few years after
their index pregnancies than both obese groups. Cross-
sectional analysis of different variables does not foretell
the prognosis of women in the future. According to our
results, obesity seems to represent a greater risk of MetS
and presentation of cardiovascular risk variables than
previous GDM, at least after a few years of delivery. The
results of multivariate analysis supported the main
findings.
A strength of our study is that all participants had
undergone OGTT screening during the index pregnancy.
In Finland, GDM screening via 75-g OGTTs is offered
to all pregnant women at risk of GDM. Current care
guidelines in Finland do not recommend OGTT screen-
ing for low-risk women – primiparous women < 25 years
old, BMI ≤ 25 kg/m2, and no family history of DM, or
multiparous women < 40 years old, no GDM in previous
pregnancy or pregnancies, and BMI ≤ 25 kg/m2 before
the current pregnancy [24].
OGTT screening has been carried out in 51.5% of
pregnancies during the past five years in our area. We
wanted to be sure that the controls really were un-
affected as regards glucose intolerance and had under-
gone OGTTs during their index pregnancies. This
situation could reflect a hidden weakness of our study,
since maybe the best controls, being part of the 48.5%
low-risk parturients who did not undergo OGTT screen-
ing during pregnancy, were excluded from the study.
Another ambiguous matter was the BMI cut-off point of
27 kg/m2, because obesity is commonly classified as BMI
of ≥ 30 kg/m2 [33]. In our subgroup analysis, we used
BMI to divide our study group into two halves, intend-
ing to reveal the effect of excess body weight on cardio-
vascular risk factors. According to the FINRISK 2012
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26.8 kg/m2 in Finland [28], so actually our cut-off point
of BMI fairly well represents average BMI among
Finnish women. Medicines agencies in Europe and in
the USA define the cut-off point of overweight as a BMI
of 27 kg/m2. Arguments for this definition have been
discussed in detail earlier [29].
Women who have had GDM are advised to have glu-
cose tolerance assessed postpartum [24,34]. The low rate
of attendance at follow-up suggests that many healthcare
providers may not recognize GDM as an initial warning
sign of predisposition to MetS. In Finland, there is no
consensus of opinion regarding how to monitor obese
women after normal pregnancy, but according to our re-
sults, we suggest that unaffected obese women should
undergo screening for at least cardiovascular risk factors
after delivery. Paying attention to patients with patho-
logical OGTT results as well as an overweight condition
during and after pregnancy helps healthcare profes-
sionals to identify women who may be at risk of devel-
oping MetS.
Conclusions
In conclusion, the risk of metabolic syndrome was 2.4
times higher after GDM compared with normoglycaemic
pregnancy, but the risk factors of coronary heart disease
were even more evident in women with excess body
weight. Women with previous GDM, particularly obese
ones, and also unaffected obese women should not miss
the opportunity to prevent future metabolic disease.
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